Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
  • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/08—Bridged systems
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to heterocyclic compounds, their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/or beta-lactam compounds, for the prevention or treatment of bacterial infections.
• the present invention also relates to the use of these compounds as ⁇ -lactamase inhibitors and/or as antibacterial agents.
• the objective of the present invention is to provide heterocyclic compounds that can be used as antibacterial agents and/or beta-lactamase inhibitors.
• An objective of the present invention is also to provide heterocyclic compounds that can be used for the prevention or for the treatment of bacterial infections.
• Another objective of the present invention is to provide heterocyclic compounds that can overcome bacterial antibiotic resistance.
• An objective of the invention is also to provide pharmaceutical compositions comprising such heterocyclic compounds, optionally in combination with one or more other antibacterial agent, for the prevention or for the treatment of bacterial infections and which can overcome bacterial antibiotic resistance.
• R 1 represents a carbon-linked, unsubstituted or substituted by one or more T 1 , aromatic, saturated, totally or partially unsaturated 4-, 5- or 6-membered heterocycle comprising at least one nitrogen atom ; -CN ; -C(0)NHQ 1 ; - C(0)NHOQ 1 ; -C(0)NH-NHQ 1 ; -C(0)0-NHQ 1 ; -C(0)OQ 1 ; -(CH 2 ) m OC(0)OQ 1 ; -
• ⁇ R 2 represents O or NOQ 5 ;
• R 3 represents S0 3 H, CFHC0 2 H or CF 2 C0 2 H ;
• Q 1 and Q 2 unsubstituted or substituted by one or more T 2 , identical or different, independently represent a CrC 3 -alkyl ; -(CH 2 ) n -(4-, 5- or 6-membered heterocycle) ; or
• Q 3 and Q 4 identical or different, independently represent a hydrogen atom or a d- C 3 -alkyl ;
• ⁇ Q 5 unsubstituted or substituted by one or more T 3 , represents CrC 3 -alkyl ; Ci-C 3 - fluoroalkyl ; -(CH 2 ) n -C 3 -C 6 -cycloalkyl ; -(CH 2 ) n -C 3 -C 6 -cyclofluoroalkyl ; -(CH 2 ) n -(4-, 5- or 6-membered aromatic, saturated, totally or partially unsaturated heterocycle comprising at least one nitrogen atom) ; or
• Q 5 represents a hydrogen atom ; (CH 2 ) p OQ 6 ; -(CH 2 ) q -CN ; -(CH 2 ) p OC(0)Q 6 ; - (CH 2 ) q -C(0)OQ 6 ; -(CH 2 ) p -OC(0)OQ 6 ; -(CH 2 ) p -OC(0)NQ 6 Q 7 ; -(CH 2 ) q - C(0)NQ 6 Q 7 ; -(CH 2 ) q -C(0)NQ 6 OQ 7 ; -(CH 2 ) q -C(0)NQ 6 -NQ 6 Q 7 ; -(CH 2 ) P - NQ 6 C(0)Q 7 ; -(CH 2 ) p NQ 6 S(0) 2 Q 7 ; -(CH 2 ) p NQ 6 S(0) 2 NQ 6 Q 7 ; -(CH 2 ) P - NQ 6 S(0) 2 Q 7 ;
• ⁇ T 1 identical or different, independently represents a fluorine atom ; -(CH 2 ) n OQ 1 ; - (CH 2 ) n -CN ; -(CH 2 ) n OC(0)Q 1 ; -(CH 2 ) n -C(0)OQ 1 ; -(CH 2 ) n -OC(0)OQ 1 ; -(CH 2 ) n -OC(0)NHQ 1 ; -(CH 2 ) n -C(0)NHQ 1 ; -(CH 2 ) n -C(0)NHOQ 1 ; -(CH 2 ) n -C(0)NH-NHQ 1 ; - (CH 2 ) n -C(0)0-NHQ ⁇ ; -(CH 2 ) n -NHC(0)Q 1 ; -(CH 2 ) n NHS(0) 2 Q 1 ;
• T 1 unsubstituted or substituted by one or more T 2 , identical or different, independently represents Ci-C 3 _alkyl ; d-C 3 -fluoroalkyl ; 0-CrC 3 -fluoroalkyl ; - (CH 2 ) n -(4-, 5- or 6-membered aromatic, saturated, totally or partially unsaturated heterocycle comprising at least one nitrogen atom) ;
• ⁇ T 2 identical or different, independently represents OH ; NH 2 or CONH 2 ;
• ⁇ T 3 identical or different, independently represents a fluorine atom ; CrC 3 -alkyl ;
• ⁇ m identical or different, independently represents 1 or 2 ;
• ⁇ n identical or different, independently represents 0, 1 , 2 or 3 ;
• ⁇ p identical or different, independently represents 2 or 3 ;
• ⁇ q identical or different, independently represents 1 , 2 or 3 ;
• any nitrogen atom present within a heterocycle or present within group wherein it is trisubstituted thus forming a tertiary amino group, can be further quaternized by a methyl group ;
• the compound according to the invention is selected from the compounds of formulae (A) a
• R 1 , R 2 and R 3 are defined according to formula (I).
• the compound according to the invention is selected from the compounds of formulae (A1 ), (A2), (B1 ) and (B2)
• the compound according to the invention is selected from the compounds of formulae (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * )
• R 1 , R 2 , R 3 and Q 5 are defined according to formula (I).
• R 1 preferably represents a carbon-linked, unsubstituted or substituted by one or more T 1 , aromatic, saturated, totally or partially unsaturated 4-, 5- or 6-membered heterocycle comprising at least one nitrogen atom ; - CN ; -C(0)NHQ 1 ; -C(0)NHOQ 1 ; -C(0)NH-NHQ 1 ; -C(0)0-NHQ 1 ; -C(0)OQ 1 ; - (CH 2 )OC(0)OQ 1 ; -(CH 2 ) 2 OC(0)OQ 1 ; -(CH 2 )OQ 1 ; -(CH 2 )OQ 1 ; -(CH 2 ) 2 OQ 1 ; -(CH 2 )OC(0)Q 1 ; - (CH 2 ) 2 OC(0)Q 1 ; -(CH 2 )-OC(0)NQ 1 Q 2 ; -(CH 2 ) 2 OC(0)NQ 1 Q 2 ; -(CH 2 )NHC(0)Q
• R 1 represents a carbon-linked, unsubstituted or substituted by one or more T 1 , aromatic, saturated, totally or partially unsaturated 4-, 5- or 6-membered heterocycle comprising at least one nitrogen atom ; -CN ; -C(0)NHQ 1 ; - C(0)NHOQ 1 ; -C(0)NH-NHQ 1 ; -(CH 2 ) 2 OQ 1 .
• R 1 may represent a carbon-linked, unsubstituted or substituted by one or more T 1 , aromatic, saturated, totally or partially unsaturated 4-, 5- or 6-membered heterocycle that comprises at least one nitrogen atom.
• Such a 4-, 5- or 6-membered heterocycle may further comprise one or more heteroatoms, for example 1 , 2 or 3 further heteroatoms, preferably selected from N, O, S, S(O) or S(0) 2 .
• R 3 preferably represents S0 3 H or CF 2 COOH.
• Q 1 and Q 2 and the nitrogen atom to which they are bonded may form together a saturated or partially unsaturated 4-, 5- or 6- membered heterocycle comprising 1 , 2 or 3 heteroatoms.
• the resulting 4-, 5- or 6- membered heterocycle thus comprises the nitrogen atom bonded to Q 1 and Q 2 and one or two further optional heteroatoms.
• Q 3 and Q 4 identical or different, preferably represent H or methyl.
• Q 6 and Q 7 and the nitrogen atom to which they are bonded may form together a saturated or partially unsaturated 4-, 5- or 6- membered heterocycle comprising 1 , 2 or 3 heteroatoms.
• the resulting 4-, 5- or 6- membered heterocycle thus comprises the nitrogen atom bonded to Q 6 and Q 7 and one or two further optional heteroatoms.
• Q 1 and Q 3 are as defined above and preferably represent H or d-C 3 -alkyl
• n is as defined above;
• Ft 2 represents O or NOQ 5 ;
• Q 4 , Q 6 and Q 7 are as defined above and preferably identical or different, independently represent a hydrogen atom ; CrC 3 -alkyl.
• R 1 represents -C(0)NHQ 1 ; -C(0)OQ 1 ; -(CH 2 ) m NHQ 3
• Q 1 and Q 3 are as defined above and preferably represent H or CrC 3 -alkyl
• n is as defined above, preferably 1 ;
• Ft 2 represents O or NOQ 5 ;
• Q 5 is as defined above and preferably represents -(CH 2 ) q -C(0)NQ 6 Q 7 ; -(CH 2 ) P NQ 6 Q 7 p and q are as defined above, preferably 1 or 2;
• Q 4 , Q 6 and Q 7 are as defined above and preferably identical or different, independently represent a hydrogen atom ; CrC 3 -alkyl.
• the invention relates also to compounds of formula
• R represents alkyi, especially CrC 6 alkyi, or benzyl
• PG, PG ⁇ and PG 2 are protective groups, for example chosen among allyl, benzyl, tertbutyldimethylsilyl (TBDMS), te/t-butoxycarbonyl (Boc), etc.
• the compounds are especially intermediates compounds for the preparation of compounds of formula (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * ) according to the invention.
• alkyi refers to an aliphatic-hydrocarbon group which may be straight or branched, having 1 to 3 carbon atoms in the chain unless specified otherwise. Preferred alkyi groups have 1 or 2 carbon atoms in the chain. Specific examples of alkyi groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl. Preferably, the alkyi group is methyl or ethyl.
• fluoroalkyl refers to an alkyi group substituted with at least one fluorine atom.
• alkyi is as defined above. Specific examples of fluoroalkyl groups include but are not limited to trifluoromethyl, difluoromethyl, fluoromethyl.
• cycloalkyi refers to a saturated monocyclic or bicyclic non-aromatic hydrocarbon ring of 3 to 6 carbon atoms, preferably 3 to 4 carbon atoms, which can comprise one or more unsaturation.
• monocyclic cycloalkyi groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
• the cycloalkyl group is cyclopropyl or cyclobutyl.
• fluorocycloalkyl refers to a cycloalkyl group substituted with at least one fluorine atom.
• cycloalkyl is as defined above. Specific examples of fluorocycloalkyl groups include fluorocyclopropyl, difluorocyclopropyl, fluorocyclobutyl, difluorocyclobutyl.
• heterocycle refers to a monocyclic saturated, partially or totally unsaturated or aromatic hydrocarbon radical, preferably to a 4- to 10-membered hydrocarbon radical, comprising at least one heteroatom, such as N, O, S, S(O) or S(0) 2 .
• the heterocycle is a monocyclic saturated, partially or totally unsaturated or aromatic hydrocarbon radical, preferably a 4- to 6-membered hydrocarbon radical, comprising at least one nitrogen atom and at least one further heteroatom, such as N, O, S, S(O) or S(0) 2 .
• the carbon atoms of the heterocycle can also be oxidized to form a C(O) group.
• Suitable heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76 th Edition, CRC Press, Inc., 1995-1996, pages 2- 25 to 2-26.
• Examplary heterocycle groups include, but are not limited to, azetidinyl, oxetanyl, oxazolyl, oxazolidinyl, oxadiazolyl, pyrrolyl, pyrrolidinyl, pyridyl, tetrahydropyridinyl, piperidinyl, morpholinyl, pyrazolyl, pyrimidinyl, pyrazinyl, tetrazolyl, imidazolyl, thienyl, thiazolyl, furanyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyrazolyl, isoxazolyl, 2-pyrrolidinonyl, imidazol-2,4-dione, 1
• some compounds according to this invention may contain a basic amino group and thus may form an inner zwitterionic salt (or zwitterion) with the acidic group (R 3 ) - OSO 3 H, -OCFHCO 2 H or -OCF 2 CO 2 H and such inner zwitterionic salts are also included in this invention.
• the expression “optionally substituted” means "non-substituted or substituted by chemical groups that are further defined” or “unsubstituted or substituted chemical groups that are further defined”.
• racemate is employed herein to refer to an equal amount of two specific enantiomers.
• enantiomer is employed herein to refer to one of the two specific stereoisomers which is a non-superimposable mirror image with one other but is related to one other by reflection.
• the compounds according to the invention may include one or more asymmetric carbon atoms and may thus exist in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof.
• the compounds according to the invention can be utilized as a single isomer or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., non-superimposable stereochemical isomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation.
• optical isomers can be obtained by using optically active starting materials, by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base or by using chiral chromatography column.
• the expression “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
• the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which comprises a basic or an acidic moiety, by conventional chemical methods.
• the expression “pharmaceutically acceptable salt” refers to relatively non- toxic, inorganic and organic acid or base addition salts of the compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds.
• the acid addition salts can be prepared by separately reacting the purified compound in its purified form with an organic or inorganic acid and by isolating the salt thus formed.
• acid addition salts are the hydrobromide, hydrochloride, hydroiodide, sulfamate, sulfate, bisulfate, phosphate, nitrate, acetate, propionate, succinate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, tosylate, citrate, maleate, fumarate, tartrate, naphthylate, mesylate, glucoheptanate, glucoronate, glutamate, lactobionate, malonate, salicylate, methylenebis-b-hydroxynaphthoate, gentisic acid, isethionate, di-p-toluoyltartrate, ethanesulf
• base addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc, metal salts such as sodium, lithium, potassium, calcium, zinc or magnesium salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine.
• suitable salts may be found in Remington's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, P.H. Stahl, C.G. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-VCH, 2002 and S.M. Berge et al. "Pharmaceutical Salts" J. Pharm. Sci, 66: p.1 -19 (1977).
• Compounds according to the invention also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
• isotopes suitable for inclusion in the compounds described above are not limited to 2 H, 3 H, 11 C, 13 C, 14 C, 18 F, 19 F, 13 N, 15 N, 33 S, 34 S, 35 S, 36 S, 17 0 or 18 0.
• Isotopically-labeled compounds are useful in drug and/or substrate tissue distribution studies. Substitution with heavier isotopes such as deuterium ( 2 H) affords greater metabolic stability (for example increased in vivo half-life or reduced dosage requirements).
• Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in replacement of the non- labeled reagent otherwise employed.
• the invention provides compounds having antibacterial properties and/or compounds acting as ⁇ -lactamase inhibitors.
• the invention also provides a process for the preparation of a compound according to the invention.
• the invention provides a process for the preparation of compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention.
• General processes according to the invention are represented in schemes 1 to 3 wherein R 1 represents various substituents.
• schemes 1 to 4 can be adapted for preparing further compounds according to the invention. Further processes for the preparation of compounds according to the invention can be derived from the processes of schemes 1 to 4.
• the invention also provides the use of the compounds according to the invention in the control of bacteria. The compound according to the invention is then usually used in combination with at least one pharmaceutically acceptable excipient.
• compositions preferably a pharmaceutical composition, comprising at least one compound according to the invention in mixture with a pharmaceutically acceptable excipient.
• composition according to the invention may thus comprise at least one compound selected from compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * ) in mixture with a pharmaceutically acceptable excipient.
• composition according to the invention can further comprise at least one or more antibacterial agent(s), preferably at least one of these antibacterial agents is a beta- lactam.
• beta-lactam or " ⁇ -lactam” refers to antibacterial compounds comprising a ⁇ - lactam unit, i.e. a ⁇ -lactam chemical group or moiety.
• pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” is employed for any excipient, solvent, dispersion medium, absorption retardant, diluent or adjuvant etc., such as preserving or antioxidant agents, fillers, binders, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial agents, isotonic and absorption delaying agents and the like, that does not produce a secondary reaction, for example an allergic reaction, in humans or animals.
• excipients include mannitol, lactose, magnesium stearate, sodium saccharide, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, starch, lactose, dicalcium phosphate, sucrose, kaolin, magnesium carbonate, wetting agents, emulsifying agents, solubilizing agents, sterile water, saline, pH buffers, non-ionic surfactants, lubricants, stabilizing agents, binding agents and edible oils such as peanut oil, sesame oils and the like.
• various excipients commonly used in the art may be included.
• compositions are well known to a person skilled in the art, and include those described in Remington's Pharmaceutical Sciences (Mack Publishing Company, Easton, USA, 1985), Merck Index (Merck & Company, Rahway, N.J.), Gilman et al (Eds. The pharmacological basis of therapeutics, 8 th Ed., Pergamon press., 1990). Except insofar as any conventional media or adjuvant is incompatible with the active ingredient according to the invention, its use in the therapeutic compositions is contemplated.
• antibacterial agent refers to any substance, compound or their combination capable of inhibiting, reducing or preventing growth of bacteria, inhibiting or reducing ability of bacteria to produce infection in a subject, or inhibiting or reducing ability of bacteria to multiply or remain infective in the environment, or decreasing infectivity or virulence of bacteria.
• the antibacterial agent can be selected among the following families: aminoglycosides, beta-lactams, glycylcyclines, tetracyclines, quinolones, fluoroquinolones, glycopeptides, lipopeptides, macrolides, ketolides, lincosamides, streptogramins, oxazolidinones and polymyxins alone or in mixture.
• the further antibacterial agent is selected among the beta-lactam families, and more preferably among penicillin, cephalosporins, penems, carbapenems and monobactam, alone or in mixture.
• the antibacterial agent is preferably selected in the group consisting of amoxicillin, ampicillin, azlocillin, mezocillin, apalcillin, hetacillin, bacampicillin, carbenicillin, sulbenicillin, temocillin, ticarcillin, piperacillin, mecillinam, pivmecillinam, methicillin, ciclacillin, talampacillin, aspoxicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, nafcillin, and pivampicillin, alone or in mixture.
• the antibacterial agent is preferably selected in the group consisting of cefatriazine, cefazolin, cefoxitin, cephalexin, cephradine, ceftizoxime, cephacetrile, cefbuperazone, cefprozil, ceftobiprole, ceftobiprole medocaril, ceftaroline, ceftaroline fosaminyl, cefalonium, cefminox, ceforanide, cefotetan, ceftibuten, cefcapene pivoxil, cefditoren pivoxil, cefdaloxime cefroxadine, ceftolozane and S-649266, cephalothin, cephaloridine, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cephacetrile, cefot
• the antibacterial agent is preferably selected in the group consisting of imipenem, doripenem, meropenem, biapenem, ertapenem and panipenem, alone or in mixture.
• the antibacterial agent is preferably selected in the group consisting of aztreonam, tigemonam, carumonam, BAL30072 and nocardicin A, alone or in mixture.
• the present invention also relates to a composition comprising at least a compound of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention and ceftazidime.
• the present invention also provides a kit comprising:
• composition comprising one or more antibacterial agents, preferably at least one of these antibacterial agents is a beta-lactam.
• the two compositions can each be prepared separately with one specific pharmaceutically acceptable carrier, and can then be mixed, especially extemporaneously.
• the present invention also relates to a kit comprising :
• a pharmaceutical composition comprising at least a compound of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * ) according to the invention; and
• the present invention also refers to a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention for its use as a medicine.
• the present invention also refers to a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention for its use for the preparation of a medicine.
• the present invention also refers to a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention for its use as an antibacterial agent.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to the use of a pharmaceutical composition according to the invention for the preparation of an antibacterial agent comprising medicine.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to the use of a pharmaceutical composition according to the invention for the preparation of a beta-lactamase inhibitor comprising medicine.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to the use of a pharmaceutical composition according to the invention for the preparation of a medicine comprising an antibacterial agent and a beta-lactamase inhibitor.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to the use of a pharmaceutical composition according to the invention or to the use of a kit according to the invention for the treatment or for the prevention of at least one bacterial infection.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to the use of a pharmaceutical composition according to the invention or to the use of a kit according to the invention for the preparation of a medicine useful in the treatment or in the prevention of at least one bacterial infection.
• prevention means the administration of a compound or composition according to the invention in order to prevent infection by bacteria or to prevent occurrence of related infection and/or diseases.
• prevention also encompass the administration of a compound or composition according to the present invention in order preventing at least one bacterial infection, by administration to a patient susceptible to be infected, or otherwise at a risk of being infected by this bacteria.
• treatment is intended to mean in particular the administration of a treatment comprising a compound or composition according to the invention to a patient suffering from an infection.
• treatment also refer to administering a compound or composition according to the invention, optionally in combination with one or more further antibacterial agent, in order:
• infection or "bacterial infection” as used herein, include the presence of bacteria, in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject.
• infection or "bacterial infection” in addition to referring to the presence of bacteria also refer to normal flora, which is not desirable.
• infection includes infection caused by bacteria.
• bacterial infections are urinary tract infection (UTI), kidney infections (pyelonephritis), gynecological and obstetrical infections, respiratory tract infection (RTI), acute exacerbation of chronic bronchitis (AECB), Community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), ventilator associated pneumonia (VAP), intra-abdominal pneumonia (IAI), acute otitis media, acute sinusitis, sepsis, catheter-related sepsis, chancroid, chlamydia, skin infections, bacteremia.
• UMI urinary tract infection
• kidney infections kidney infections
• RTI respiratory tract infection
• RTI respiratory tract infection
• AECB acute exacerbation of chronic bronchitis
• CAP Community-acquired pneumonia
• HAP hospital-acquired pneumonia
• VAP ventilator associated pneumonia
• IAI intra-abdominal pneumonia
• growth refers to the growth of one or more microorganisms and includes reproduction or population expansion of a microorganism, such as bacteria.
• the term also includes maintenance of on-going metabolic processes of a microorganism, including processes that keep the microorganism alive.
• bacteria are chosen amongst gram-positive bacteria or gram- negative bacteria, preferably gram-negative bacteria. According to the invention, bacteria can be also chosen among bacteria producing "beta-lactamase” or " ⁇ -lactamase”. These bacteria are well known by the person skilled in the art.
• beta-lactamase or " ⁇ -lactamase” includes enzymes that are produced by bacteria and that have the ability to hydrolyze, either partially or completely, the beta-lactam ring present in a compound such as an antibacterial agent.
• the bacteria according to the invention is preferably chosen among Staphylococcus, Streptococcus, Staphylococcus species (including Staphylococcus aureus, Staphylococcus epidermidis), Streptococcus species (including Streptococcus pneumonia, Streptococcus agalactiae), Enterococcus species (including Enterococcus faecalis and Enterococcus faecium).
• the bacteria according to the invention is preferably chosen among Acinetobacter species (including Acinetobacter baumannii), Citrobacter species, Escherichia species (including Escherichia coli), Haemophilus influenza, Morganella morganii, Klebsiella species (including Klebsiella pneumonia), Enterobacter species (including Enterobacter cloacae), Neisseria gonorrhoeae, Burkholderia species (including Burkholderia cepacia), (Proteus species (including Proteus mirabilis), Serratia species (including Serratia marcescens), Pseudomonas aeruginosa.
• Acinetobacter species including Acinetobacter baumannii
• Citrobacter species including Escherichia coli
• Haemophilus influenza Morganella morganii
• Klebsiella species including Klebsiella pneumonia
• Enterobacter species including Enterobacter cloacae
• the invention thus preferably refers to a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention or to a pharmaceutical composition according to the invention or to a kit according to the invention for its use for the treatment or for the prevention of a bacterial infection, preferably caused by bacteria producing one or more beta-lactamases.
• the bacteria are chosen amongst gram-positive bacteria or gram-negative bacteria, more preferably gram-negative bacteria.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), ( ⁇ ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or to a pharmaceutical composition according to the invention for the preparation of a medicine for the treatment or for the prevention of a bacterial infection, preferably caused by bacteria producing one or more beta- lactamases.
• the bacteria are chosen amongst gram-positive bacteria or gram- negative bacteria, more preferably gram-negative bacteria.
• the present invention also refers to a kit according to the invention, for its simultaneous, separated or sequential administration to a patient in need thereof in the treatment or in the prevention of bacterial infections, preferably caused by bacteria producing one or more beta-lactamases.
• the bacteria are chosen amongst gram-positive bacteria or gram-negative bacteria, more preferably gram-negative bacteria.
• the present invention also refers to a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention for its use in combination with one or more further antibacterial agents, preferably at least one of the further antibacterial agents being a beta lactam compound, for the treatment or for the prevention of bacterial infections, preferably caused by bacteria producing one or more beta-lactamases.
• the bacteria are chosen amongst gram-positive bacteria or gram-negative bacteria, more preferably gram- negative bacteria, and wherein a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention and the further antibacterial agent are administered simultaneously, separately or sequentially.
• a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention and the further antibacterial agent are administered simultaneously, separately or sequentially.
• the present invention also refers to the use of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), (B1 * ) and (B2 * ) according to the invention or of a pharmaceutical composition according to the invention or of a kit according to the invention for the prevention or for the treatment of bacterial infections, preferably of a bacterial infection, preferably caused by bacteria producing one or more beta-lactamases.
• the bacteria are chosen amongst gram-positive bacteria or gram-negative bacteria, more preferably gram-negative bacteria.
• the present invention also relates to a method for the treatment or prevention of bacterial infections, preferably caused by bacteria producing one or more beta-lactamases comprising the administration of a therapeutically effective amount of a compound selected within the compounds of formulae (I), (A), (B), (A1 ), (A2), (B1 ), (B2), (I * ), (A * ), (B * ), (A1 * ), (A2 * ), ( ⁇ ) and (B2 * ) according to the invention, or of a pharmaceutical composition according to the invention or of a kit according to the invention to a patient in need thereof.
• the bacteria are chosen amongst gram-positive bacteria or gram-negative bacteria, more preferably gram-negative bacteria.
• patient means a person or an animal at risk of being infected by bacteria or, a person or an animal being infected by bacteria, preferably by gram-positive and by gram- negative bacteria, more preferably by gram-negative bacteria.
• patient refers to a warm-blooded person or animal such as a mammal, preferably a human or a human child, who is afflicted with, or has the potential to be afflicted with one or more infections and conditions described herein.
• the identification of those subjects who are in need of treatment of herein-described diseases and conditions is well within the ability and knowledge of one skilled in the art. A veterinarian or a physician skilled in the art can readily identify, by the use of clinical tests, physical examination, medical or family history or biological and diagnostic tests, those subjects who are in need of such a treatment.
• terapéuticaally effective amount refers to an amount of a compound according to the invention, which when administered to a patient in need thereof, is sufficient to effect treatment for disease- states, conditions, or disorders for which the compound has utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or a clinician.
• the amount of a compound according to the invention which constitutes a “therapeutically effective amount” will vary, notably depending on the compound itself and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidental ⁇ with the compounds of the invention, and the age, body weight, general health, sex and diet of the patient.
• a “therapeutically effective amount” can be determined by one of ordinary skilled in the art having regard to its own knowledge, and this disclosure.
• the compound according to the invention is administered in an amount comprised between 0.1 to 30 g per day.
• the compound according to the invention may be provided in an aqueous physiological buffer solution for parenteral administration.
• the compound of the present invention is also capable of being administered in unit dose forms, wherein the expression "unit dose” means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described herein.
• the compound provided herein can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
• Such unit dose compositions may be prepared for use by oral administration, particularly in the form of tablets, simple capsules or soft gel capsules; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically in ointments, creams, lotions, gels or sprays, or via trans-dermal patches.
• the pharmaceutical composition may be conveniently administered in unit dosage form and may be prepared by any method well-known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
• Preferred formulations include pharmaceutical compositions wherein a compound according to the present invention is formulated for oral or parenteral administration.
• tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate.
• a binder such as microcrystalline cellulose, or gum tragacanth
• a diluent such as starch or lactose
• a disintegrant such as starch and cellulose derivatives
• a lubricant such as magnesium stearate
• a glidant such as colloidal silicon dioxide
• a sweetening agent such as sucrose or saccharin
• a flavoring agent such
• Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule.
• dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
• Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings and flavorings.
• the active compounds may be incorporated into fast dissolved, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
• Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate or talc in any combination.
• Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions.
• the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
• Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
• Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
• biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene- polyoxypropylene copolymers may be useful excipients to control the release of the active compound.
• Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like.
• Other potentially useful parenteral delivery systems for the active compound include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems and liposomes.
• formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions comprising, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
• Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
• Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, and may include a salicylate.
• Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
• Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations.
• Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
• the first part represents the preparation of the compounds (intermediates and final compounds) whereas the second part describes the evaluation of antibacterial activity of compounds according to the invention.
• BocON [2-(te/t-butoxycarbonyloxyimino)-2-phenylacetonitrile] bs: broad singlet
• DIAD diisopropyl azodicarboxylate
• DIPEA A/JV-diisopropylethylamine
• HATU 1 -[Bis(dimethylamino)methylene]-1 H-1 ,2,3-triazolo[4,5- £>]pyridinium-3-oxid hexafluorophosphate
• NBS /V-bromosuccinimide
• TBDMSOTf trifluoromethanesulfonic acid tert-butyldimethylsilyl ester
• TBSOTf trimethylsilyl trifluoromethanesulfonate
• Tr trityl (triphenylmethyl)
• Example 1 synthesis of sodium [(2S,5S)-2-methoxycarbonyl-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicyclo[3.2.11octan-6-yl1 sulfate
• Step 1 Preparation of intermediate 4-te/t-butyl ester 3-methyl ester (1 fl,4S,6S)-7-oxa-3- aza-bicyclo[4.1 .01heptane-3,4-dicarboxylate (1 a)
• Step 2 Preparation of intermediate 1 -te/t-butyl ester 2-methyl ester (2S,4S,5S)-5- allyloxyamino-4-hvdroxy-piperidine-1 ,2-dicarboxylate (1 b)
• Step 3 Preparation of intermediate 1 -te/t-butyl ester 2-methyl ester (2S,4S,5S)-5- allyloxyamino-4-(tert-butyl-dimethyl-silanyloxy)-piperidine-1 ,2-dicarboxylate (1 c)
• Step 4 Preparation of intermediate methyl (2S,4S,5S)-5-(allyloxyamino)-4-[ter/- butyl(dimethyl)silyl1oxy-piperidine-2-carboxylate (1 d)
• Step 5 Preparation of intermediate methyl (2S,4S,5S)-6-allyloxy-4-[ter/- butvKdimethvDsilyll oxy-7-oxo-1 ,6-diazabicyclo[3.2.11octane-2-carboxylate (1 e)
• Step 6 Preparation of intermediate methyl (2S,4S,5S)-6-allyloxy-4-hvdroxy-7-oxo-1 ,6- diazabicyclo[3.2.11octane-2-carboxylate (1 f)
• Step 8 Preparation of intermediate methyl (2S,5S)-6-allyloxy-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicyclo[3.2.11octane-2-carboxylate (1 h)
• reaction mixture was concentrated under vacuum and the residue was purified by flash chromatography on silica gel (DCM/MeOH 100/0 to 98/2) to provide intermediate methyl (2S,5S)-6-allyloxy-4-[2-(methylamino)-2-oxo-ethoxy]imino-7-oxo-1 ,6- diazabicyclo[3.2.1 ] octane-2-carboxylate (1 h) (0.153 g, 0.45 mmol, ratio Z/E: 50/50, 81 %). MS m/z ([M+H] + ) 341 .
• Step 9 Preparation of sodium [(2S,5S)-2-methoxycarbonyl-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicyclo[3.2.11octan-6-yl1 sulfate (example 1 )
• the filtrate was concentrated and purified on silica gel (DCM/acetone 100/0 to 0/100) to provide 102 mg of a colorless oil of triphenyl-(propenyl)- phosphonium [(2S,5S)-2-methoxycarbonyl-4-[2-(methylamino)-2-oxo-ethoxy]imino-7-oxo- 1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate.
• This oil was solubilized in a minimal volume of water and applied on a Dowex sodium form column (Dowex® 50WX8 hydrogen form stored with an aqueous solution of 2N NaOH and washed until neutral pH with water).
• Step 1 Preparation of intermediate (2S,5S)-6-allyloxy-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicvclo[3.2.11octane-2-carboxylic acid (2a)
• Step 2 Preparation of intermediate (2S,5S)-6-allyloxy-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicvclo[3.2.11octane-2-carboxamide (2b)
• Step 3 Preparation of sodium [(2S,5S)-2-carbamoyl-4-[2-(methylamino)-2-oxo- ethoxy1imino-7-oxo-1 ,6-diazabicvclo[3.2.11octan-6-yl1 sulfate (example 2)
• Example 3 synthesis of sodium [(2S, 5S)-4-(2-amino-2-oxo-ethoxy)imino-2-carbamoyl-7- oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate
• Step 1 preparation of intermediate methyl (2S, 5S)-6-allyloxy-4-(2-amino-2-oxo- ethoxy)imino-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylate (3a)
• step 8 methyl (2S,5S)-6-allyloxy-4,7-dioxo- 1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylate (1 g) (1.05 g, 4.13 mmol) is converted by reaction with the 2-(aminooxy)acetamide hydrochloride (0.495 g, 3.92 mmol) for 45 minutes into (2S, 5S)-6-allyloxy-4-(2-amino-2-oxo-ethoxy)imino-7-oxo-1 ,6- diazabicyclo[3.2.1 ]octane-2-carboxylate (3a) (1 .14 g, 3.49 mmol, ratio Z/E 50/50, 85%) as a yellow oil after purification by flash chromatography (DCM/MeOH : 100/0 to 95/5).
• DCM/MeOH flash chromatography
• Step 2 preparation of intermediate (2S, 5S)-6-allyloxy-4-(2-amino-2-oxo-ethoxy)imino-7- oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylic acid (3b)
• Step 3 preparation of intermediate (2S, 5S)-6-allyloxy-4-(2-amino-2-oxo-ethoxy)imino-7- oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxamide (3c)
• Step 4 preparation of sodium [(2S, 5S)-4-(2-amino-2-oxo-ethoxy)imino-2-carbamoyl-7- oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (example 3)
• the filtrate was concentrated and purified by flash chromatography on silica gel (DCM/acetone/propan-2-ol : gradient 100/0/0 to 0/100/0 to 0/0/100) to provide 40 mg of an orange oil of triphenyl-(propenyl)-phosphonium [(2S, 5S)-4-(2-amino-2-oxo- ethoxy)imino-2-carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate.
• DCM/acetone/propan-2-ol gradient 100/0/0 to 0/100/0 to 0/0/100
• Example 4 synthesis of sodium and 2,2,2-trifluoroacetate [(2S, 5S)-4- ammoniumethoxyimino)-2-carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate
• Step 1 preparation of intermediate methyl (2S, 5S)-6-allyloxy-4-[2-(ter/- butoxycarbonylamino)ethoxyimino]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylate (4a)
• methyl (2S,5S)-6-allyloxy-4,7-dioxo- 1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylate (1 g) (0.862 g, 3.39 mmol) is converted by reaction with the te/t-butyl A/-(2-aminooxyethyl)carbamate (0.568 g, 3.22 mmol) for 27 h into methyl (2S, 5S)-6-allyloxy-4-[2-(ie -butoxycarbonylamino)ethoxyimino]-7-oxo-1 ,6- diazabic
• Step 2 preparation of intermediate (2S, 5S)-6-allyloxy-4-[2-(tert-butoxycarbonylamino) ethoxyimino]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylic acid (4b)
• step 2 the intermediate (methyl (2S, 5S)-6- allyloxy-4-[2-(tert-butoxycarbonylamino)ethoxyimino]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane- 2-carboxylate (4a) (0.590 g, 1 .43 mmol) is converted into (2S, 5S)-6-allyloxy-4-[2-(tert- butoxycarbonylamino) ethoxyimino]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2-carboxylic acid (4b) in mixture with (2S, 5S)-5-[allyloxy(methoxycarbonyl)amino]-4-[2-(tert- butoxycarbonylamino)ethoxyimino]piperidine-2-carboxylic acid (0.393 g) after purification by flash chromatography on silica gel (D
• Step 3 preparation of intermediate terf-butyl A/-[2-[(2S,5S)-6-allyloxy-2-carbamoyl-7-oxo- 1 ,6-diazabicyclo[3.2.1 ]octan-4-ylidene]amino]oxyethyl]carbamate (4c)
• step 2 the mixture of (2S, 5S)-6-allyloxy-4- [2-(tert-butoxycarbonylamino) ethoxyimino]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octane-2- carboxylic acid (4b) (0.300 g, 0.753 mmol) is converted into A/-[2-[[(2S,5S)-6-allyloxy-2- carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-4-ylidene]amino]oxyethyl]carbamate (4c) (0.202 g, 2.14 mmol, 35% over 2 steps) as a Z/E 50/50 mixture after purification by flash chromatography on silica gel (DCM/propan-2-ol : 100/0 to 0/100).
• DCM/propan-2-ol 100/0 to 0/100
• Step 4 preparation of sodium [(2S, 5S)-4-[2-(te/?-butoxycarbonylamino)ethoxyimino]-2- carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (4d)
• step 4 the intermediate A/-[2-[[(2S,5S)-6- allyloxy-2-carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-4-ylidene]amino]oxyethyl] carbamate (4c) (0.237 g, 0.596 mmol) provided 135 mg of triphenyl-(propenyl)- phosphonium [(2S, 5S)-4-[2-(ie -butoxycarbonylamino)ethoxyimino]-2-carbamoyl-7-oxo- 1 ,6-diazabicyclo [3.2.1 ]octan-6-yl] sulfate after purification on silica gel (DCM/acetone/ propan-2-ol : gradient 100/0/0 to 0/100/0 to 0/0/100).
• Step 5 preparation of sodium and 2,2,2-trifluoroacetate [(2S, 5S)-4-(2- ammoniumethoxyimino)-2-carbamoyl-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (example 4)
• Example 5 synthesis of sodium and 2,2,2-trifluroacetate [(2S,5S)-4-(2-amino-2-oxo- ethoxy)imino-2-(azaniumylmethyl)-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate
• Step 1 preparation of intermediate te/t-butyl (1 S,3S,6/ : ?)-3-(hydroxymethyl)-7-oxa-4- azabicyclo[4.1 .0]heptane-4-carboxylate (5a)
• Step 2 preparation of intermediate terf-butyl (1 S,3S,6fl)-3-[[te/t-butyl(dimethyl)silyl] oxymethyl]-7-oxa-4-azabicyclo[4.1 .0]heptane-4-carboxylate (5b)
• Step 3 preparation of intermediate terf-butyl (2S,4S,5S)-5-(allyloxyamino)-2-[[te/t- butyl(dimethyl)silyl]oxymethyl]-4-hydroxy-piperidine-1 -carboxylate (5c)
• Step 5 preparation of intermediate (3S,4S,6S)-/V-allyloxy-4-[ieri-butyl(dimethyl)silyl]oxy-6- [[ie -butyl(dimethyl)silyl]oxymethyl]piperidin-3-amine (5e)
• Step 7 preparation of intermediate (2S,4S,5S)-6-allyloxy-4-hydroxy-2-(hydroxymethyl)- 1 ,6-diazabicyclo[3.2.1 ]octan-7-one (5g)
• Step 8 preparation of intermediate [(2S,4S,5S)-6-allyloxy-4-hydroxy-7-oxo-1 ,6- diazabicyclo[3.2.1 ]octan-2-yl]methyl methanesulfonate (5h)
• Step 9 preparation of intermediate te/t-butyl A/-[[(2S,4S,5S)-6-allyloxy-4-hydroxy-7-oxo- 1 ,6-diazabicyclo[3.2.1 ]octan-2-yl]methyl]carbamate (5i)
• Step 10 preparation of intermediate te/t-butyl A/-[[(2S,5S)-6-allyloxy-4,7-dioxo-1 ,6- diazabicyclo[3.2.1 ]octan-2-yl]methyl]carbamate (5j)
• reaction was stirred for 2h30 at rt then the mixture was washed with a saturated NaHC0 3 aqueous solution, a 15% Na 2 S 2 0 3 solution, water, dried oved Na 2 S0 4 , filtered and concentrated under vacuum.
• Step 1 1 preparation of intermediate te/t-butyl A/-[[(2S,5S)-6-allyloxy-4-(2-amino-2-oxo- ethoxy)imino-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-2-yl]methyl]carbamate (5k)
• Step 12 preparation of intermediate sodium [(2S,5S)-4-(2-amino-2-oxo-ethoxy)imino-2- [(te/t-butoxycarbonylamino)methyl]-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (5I)
• This oil was solubilized in a minimal volume of a mixture of water and acetone and applied on a Dowex sodium form column (Dowex® 50WX8 hydrogen form stored with an aqueous solution of 2N NaOH and washed until neutral pH with water).
• Dowex sodium form column Dowex® 50WX8 hydrogen form stored with an aqueous solution of 2N NaOH and washed until neutral pH with water.
• Step 13 preparation of 2,2,2-trifluroacetate and sodium [(2S,5S)-4-(2-amino-2-oxo- ethoxy)imino-2-(azaniumylmethyl)-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (example 5)
• Example 6 synthesis of 2,2,2-trifluroacetate and sodium [(2S, 5S)-4-(2-amino-2-oxo- ethoxy)imino-2-(azaniumylmethyl)-7-oxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate
• Step 2 preparation of 2,2,2-trifluroacetate and sodium [(2S,5S)-2-(azaniumylmethyl)-4,7- dioxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (example 6)
• step 13 sodium [(2S,5S)-2-[(tert- butoxycarbonylamino)methyl]-4,7-dioxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (6a) (0.0095 g, 0.245 mmol) is converted into 2,2,2-trifluroacetate and sodium [(2S,5S)-2- (azaniumylmethyl)-4,7-dioxo-1 ,6-diazabicyclo[3.2.1 ]octan-6-yl] sulfate (example 6) (0.010 g, 0.024 mmol, quantitative yield) as an orange oil.
• Enzyme activity was monitored by spectrophotometric measurement of nitrocefin (NCF - TOKU-E, N005) hydrolysis at 485nm, at room temperature and in assay buffer A: 100mM Phosphate pH7, 2% glycerol and 0.1 mg/ ml_ Bovine serum albumin (Sigma, B4287).
• Enzymes were cloned in E. coli expression vector, expressed and purified in house using classical procedures.
• To a transparent polystyrene plate (Corning, 3628) were added in each well 5 ⁇ _ DMSO or inhibitor dilutions in DMSO and 80 ⁇ _ enzyme in buffer A.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cephalosporin Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (11)

Applications Claiming Priority (4)

Publications (1)

Family

ID=55642466

Family Applications (2)

Family Applications After (1)

Country Status (14)

Cited By (2)

Families Citing this family (2)

Citations (4)

Family Cites Families (10)

• 2016
  • 2016-03-30 US US15/563,483 patent/US10570131B2/en active Active
  • 2016-03-30 TW TW105110155A patent/TW201639853A/zh unknown
  • 2016-03-30 RU RU2017133745A patent/RU2715058C2/ru active
  • 2016-03-30 WO PCT/EP2016/056845 patent/WO2016156346A1/en not_active Ceased
  • 2016-03-30 AU AU2016239207A patent/AU2016239207A1/en not_active Abandoned
  • 2016-03-30 CN CN201680020427.5A patent/CN107438610A/zh active Pending
  • 2016-03-30 KR KR1020177031506A patent/KR20170131687A/ko not_active Withdrawn
  • 2016-03-30 MX MX2017012539A patent/MX2017012539A/es unknown
  • 2016-03-30 BR BR112017020826-1A patent/BR112017020826A2/pt not_active Application Discontinuation
  • 2016-03-30 CA CA2980109A patent/CA2980109A1/en not_active Abandoned
  • 2016-03-30 JP JP2017551331A patent/JP2018510190A/ja active Pending
  • 2016-03-30 EP EP16712866.9A patent/EP3277685B1/en active Active
  • 2016-03-30 HK HK18104010.8A patent/HK1244791A1/zh unknown
  • 2016-03-30 WO PCT/EP2016/056842 patent/WO2016156344A1/en not_active Ceased
• 2017
  • 2017-09-28 CL CL2017002449A patent/CL2017002449A1/es unknown

Patent Citations (4)

Non-Patent Citations (9)

Also Published As

Similar Documents

Legal Events